The American Journal of Managed Care

Addressing Knowledge Gaps and Treatment Strategies in Bronchiectasis

A pulmonary specialist shares his approach to treating patients with bronchiectasis, highlighting gaps in knowledge that impact management practices. What are the current gaps in knowledge regarding ...
UPI

First drug to treat bronchiectasis lung condition approved by FDA

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...
Seeking Alpha

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed (INSM) to Host Investor ...
Seeking Alpha

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

—Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J., Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (INSM), a ...
Healio

FDA grants brensocatib priority review for bronchiectasis

Please provide your email address to receive an email when new articles are posted on . Brensocatib given as 25 mg performed better than placebo when assessing rate of pulmonary exacerbations and lung ...
Canadian Medical Association Journal

A 67-year-old woman with bronchiectasis and acute worsening respiratory symptoms

A 67-year-old woman with known bronchiectasis presents with 2 days of worsening dyspnea and cough productive of 2 tablespoons of green sputum streaked with blood. She reports struggling to walk 1 city ...